Shen Zhen Shi

People with end stage kidney disease (ESKD) who require dialysis have a much higher risk of developing cardiovascular disease compared to the general population, with heart problems causing over half of the deaths in this group. This trial is studying whether taking low dose aspirin daily can safely reduce cardiovascular events in these dialysis patients. The study is a Phase 4, multi-center, randomized controlled trial designed to provide clear evidence about aspirin's benefits and risks in this specific population, where existing data is limited. Participants will be randomly assigned to receive either a daily 100 mg aspirin tablet or a matching placebo. The trial uses the Chinese peritoneal dialysis and hemodialysis registry to efficiently screen and recruit patients and collect data during routine dialysis care. Follow-up visits occur every six months as part of regular clinical care, and the study will continue until enough cardiovascular events have occurred, expected to take about five years. During the study, participants will have their health monitored through routine clinic visits every six months, with data collected on cardiovascular events and safety. The main outcome measured is the number of participants experiencing major cardiovascular events over the study period. An independent board will oversee safety and study progress. The trial uses intention-to-treat analysis and aims to minimize participant burden by integrating study procedures into usual care.

Researchers are investigating the effects of thrombus aspiration (TA) in patients experiencing ST-segment Elevation Myocardial Infarction (STEMI) who have a high thrombus burden, indicated by a TIMI thrombus grade of 3 or higher. This prospective, multicenter, open-label, randomized controlled trial aims to compare outcomes between patients treated with or without manual thrombus aspiration during primary percutaneous coronary intervention (PPCI) performed within 12 hours of symptom onset. The goal is to assess if TA reduces major cardiovascular events including cardiovascular death, recurrent heart attacks, stent thrombosis, target vessel revascularization within 180 days, or stroke within 30 days. Participants are randomly assigned in a 1:1 ratio to receive either primary PCI with manual thrombus aspiration or PCI alone without thrombus aspiration. Both procedures are performed as part of the treatment for STEMI patients with high thrombus burden. The study evaluates the safety and efficacy of adding thrombus aspiration to the standard PCI process. During the study, patients will be monitored for up to 180 days to track the occurrence of major adverse cardiovascular events. Researchers will collect data on cardiovascular death, recurrent myocardial infarction, stent thrombosis, need for target vessel revascularization, and stroke. Follow-up evaluations will help determine the overall impact of thrombus aspiration on patient outcomes after STEMI treatment.